更新于：2024-12-12
Hydrochlorothiazide
氢氯噻嗪
更新于：2024-12-12
概要
基本信息
简介氢氯噻嗪是一种小分子药物，作用于噻嗪类敏感氯化钠协同转运蛋白，是噻嗪类敏感氯化钠协同转运蛋白抑制剂。它的适应症包括尿崩症、水肿、高血压和肾结石等。氢氯噻嗪最初由诺华制药公司研发，并于1959年2月12日获得首次批准。该药物通过抑制NCC，减少肾脏中的钠重吸收，从而促进尿液排泄和水分排出，达到利尿的效果。此外，它还可以降低血压和防止肾结石形成。虽然氢氯噻嗪可以缓解症状，但也存在一些不良反应，如低钾血症、头晕、乏力等，需要在医生的指导下使用。总体而言，氢氯噻嗪是一种常用的利尿药和降压药，对多种疾病的治疗具有重要作用。 |
药物类型 小分子化药 |
别名 HCTZ、Hydrochlorothiazide (JP17/USP/INN)、氢氯噻嗪微片 + [10] |
靶点 |
作用机制 NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-02-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C7H8ClN3O4S2 |
InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N |
CAS号58-93-5 |
关联
241
项与 氢氯噻嗪 相关的临床试验氢氯噻嗪片（25mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention
Clinical study of midapril hydrochloride combined with hydrochlorothiazide in the treatment of essential hypertension
100 项与 氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
7,618
项与 氢氯噻嗪 相关的文献（医药）2025-01-01JOURNAL OF ETHNOPHARMACOLOGY
Antiurolithic activity of Zaleya pentandra (L.) C Jeffrey in ethylene glycol-induced calcium oxalate crystal rat model; A scientific validation of traditional use for kidney stone prevention
Article
作者: Akhtar, Muhammad Furqan ; Anwar, Fareeha ; Riaz, Muhammad ; Khan, Aslam ; William, Sumaira ; khan, Aslam ; Ahmad, Rizwan
ETHNOPHARMACOLOGICAL RELEVANCE:
Traditional herbal remedies have been used for treating nephrolithiasis, but the relevant scientific evidence is limited. Zaleya pentandra (L.) C. Jeffrey is traditionally used for the prevention of kidney stones in various cultures. However, its efficacy has not been scientifically studied.
AIM OF THE STUDY:
This study aimed to investigate the antiurolithic activity of Zaleya pentandra, and validate its traditional used for preventing kidney stones.
MATERIALS AND METHODS:
The crude ethanolic extract of Z. pentandra (Zp.Crd) was evaluated through in vitro and in vivo studies. In vitro experiments assessed its impact on crystal count and morphology in metastable calcium oxalate solutions. In vivo studies involved diuretic and ethylene glycol-induced calcium oxalate crystal formation in male Wistar rats.
RESULTS:
Zp.Crd transforms calcium oxalate crystals from harmful calcium oxalate monohydrate (COM) to calcium oxalate dihydrate (COD). In vivo, Zp.Crd exhibited dose-dependent (30-300 mg/kg) diuretic activity in rats by significantly increasing urinary sodium (Na+) and potassium (K+) excretion, similar to the standard diuretic hydrochlorothiazide (HCT). In the urolithiasis model, Zp.Crd exhibited dose-dependent antiurolithic effects by reducing kidney crystals and significantly altering lithogenic factors induced by ethylene glycol, including crystalluria, oxaluria, calcium, creatinine, and urea, in the urine and serum of treated rats. Zp.Crd also exhibited antioxidant effects, effectively combating oxidative lithogenic stress in rats.
CONCLUSION:
Zp.Crd has been shown to demonstrate antiurolithic activity against CaOx stones through CaOx crystal inhibition, diuretic activity, antioxidant properties, hypocalciuric effects, and hypercitrauric actions. The findings underscore Zp.Crd's potential as a viable alternative or supplemental therapy to current urolithiasis treatments, paving the door for further clinical trials and its inclusion into modern medical practices.
2025-01-01Contemporary Clinical Trials
Characteristics of VA hospitals by participation status in a large pragmatic embedded clinical trial
Article
作者: Leatherman, Sarah M ; Cushman, William C. ; Ferguson, Ryan E ; Leatherman, Sarah M. ; Cushman, William C ; Ishani, Areef ; Dupuis, Genevieve ; Ferguson, Ryan E.
BACKGROUND:
The Diuretic Comparison Project (DCP) was a multi-center, embedded pragmatic trial conducted within the VA healthcare system comparing chlorthalidone and hydrochlorothiazide in preventing major adverse cardiovascular events and non-cancer deaths in hypertensive patients. Study procedures were decentralized, and facility leadership first had to agree and accept study procedures before staff approached participants. Recent evidence suggests facilities that choose and choose not to participate in trials may differ and this study considered such differences within DCP.
METHODS:
A cross-sectional comparison of facilities participating in DCP was conducted with data from the study start (June 2016) including: 2016 American Community Survey, 2016 Strategic Analytics for Improvement and Learning reports, star ratings, and 2014 hospital complexity. Characteristics of participating and non-participating centers were compared using logistic regression, including county-level socio-economic features and hospital-level performance.
RESULTS:
Of 144 VA medical centers, leadership at 75 centers (52 %) initiated participation. Facilities in highly-urban and higher median income counties were more likely to participate, as were higher-complexity facilities. Facilities with research experience were 2.18 times as likely to participate. No other hospital performance metrics or county-level demographics were associated with participation.
CONCLUSIONS:
Overall, this study suggests research exposure and quality care metrics may impact a facility's decision to participate. These results highlight key considerations for recruitment to multi-site, and particularly pragmatic, clinical trials. Consideration of supporting facilities that have not historically participated in research may be fruitful for recruitment. These results emphasize the importance of education about pragmatic study design and its integration with clinical care.
2024-12-31BLOOD PRESSURE
Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study
Article
作者: Marques Pereira, Raul ; Polónia, Jorge
PURPOSE:
In a prospective open study, with intervention, conducted in Primary Health Care Units by General Practitioners (GPs) in Portugal, the effectiveness of a single pill of candesartan/amlodipine (ARB/amlodipine), as the only anti-hypertension (anti-HTN) medication, in adult patients with uncontrolled HTN (BP > 140/or > 90 mm Hg), either previously being treated with anti-HTN monotherapies (Group I), or combinations with hydrochlorothiazide (HCTZ) (Group II), or not receiving medication at all (Group III), was evaluated across 12-weeks after implementation of the new therapeutic measure.
MATERIALS AND METHODS:
A total of 118 GPs recruited patients with uncontrolled HTN who met inclusion/exclusion criteria. Participants were assigned, according to severity, one of 3 (morning) fixed combination candesartan/amlodipine dosage (8/5 or 16/5 or 16/10 mg/day) and longitudinally evaluated in 3 visits (v0, v6 and v12 weeks). Office blood pressure was measured in each visit, and control of HTN was defined per guidelines (BP< 140/90 mmHg).
RESULTS:
Of the 1234 patients approached, 752 (age 61 ± 10 years, 52% women) participated in the study and were assigned to groups according to previous treatment conditions. The 3 groups exhibited a statistically significant increased control of blood pressure after receiving the fixed combination candesartan/amlodipine dosage. The overall proportion of controlled HTN participants increased from 0,8% at v0 to 82% at v12. The mean arterial blood pressure values decreased from SBP= 159.0 (± 13.0) and DBP= 91.1 (± 9.6) at baseline to SBP= 132,1 (± 11.3) and DBP= 77,5 (± 8.8) at 12 weeks (p < 0.01). Results remained consistent when controlling for age and sex.
CONCLUSION:
In patients with uncontrolled HTN, therapeutic measures in accordance with guidelines, with a fixed combination candesartan/amlodipine, allowed to overall achieve HTN control at 12 weeks in 82% of previously uncontrolled HTN patients, reinforcing the advantages of these strategies in primary clinical practice.
100 项与 氢氯噻嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 尿崩症 | 中国 | 1981-01-01 | |
| 水肿 | 中国 | 1981-01-01 | |
| 肾石病 | 中国 | 1981-01-01 | |
| 高血压 | 美国 | 1959-02-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 日本 | 2006-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 13,523 | Chlorthalidone (with prior MI or stroke at baseline) | 製淵衊選衊築淵顧網鬱(選鬱襯網糧願鑰觸醖鑰) = 淵鬱壓範襯鑰獵遞蓋鬱 蓋簾選觸齋醖繭繭壓襯 (壓淵鬱獵蓋齋網淵繭選 ) 更多 | 积极 | 2024-05-01 | ||
(with prior MI or stroke at baseline) | 製淵衊選衊築淵顧網鬱(選鬱襯網糧願鑰觸醖鑰) = 獵艱觸衊鬱憲窪積襯鑰 蓋簾選觸齋醖繭繭壓襯 (壓淵鬱獵蓋齋網淵繭選 ) 更多 | ||||||
N/A | 706 | Low thiazide dose | 築獵築艱積餘襯衊憲襯(選齋築蓋鑰鏇鹽網願積) = 壓顧壓壓憲餘窪顧蓋製 蓋鑰築遞鹹蓋築鹹範淵 (餘蓋繭鏇鬱膚蓋齋餘構 ) 更多 | 积极 | 2024-05-01 | ||
Medium thiazide dose | 築獵築艱積餘襯衊憲襯(選齋築蓋鑰鏇鹽網願積) = 艱願窪願鏇餘選製膚壓 蓋鑰築遞鹹蓋築鹹範淵 (餘蓋繭鏇鬱膚蓋齋餘構 ) 更多 | ||||||
临床3期 | 416 | Placebo oral capsule (Placebo) | 鹽鏇壓廠鑰糧範餘積製(蓋艱製窪糧選範積艱齋) = 鬱夢遞淵淵膚憲鬱襯襯 構蓋鑰鏇鑰襯製製繭襯 (鹹膚觸齋壓醖獵網窪膚, 壓襯窪鹹築艱餘範範襯 ~ 範築選製糧鑰膚鹹觸築) 更多 | - | 2024-02-01 | ||
(12.5 mg Hydrochlorothiazide) | 鹽鏇壓廠鑰糧範餘積製(蓋艱製窪糧選範積艱齋) = 製製醖窪遞遞繭蓋窪鹽 構蓋鑰鏇鑰襯製製繭襯 (鹹膚觸齋壓醖獵網窪膚, 衊鏇齋築夢鬱範齋製遞 ~ 範壓鹹觸夢糧範廠遞遞) 更多 | ||||||
临床3期 | 230 | Placebo | 淵鹹繭構廠獵鏇範網壓(餘壓鬱蓋鬱鑰遞憲顧壓) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex 壓壓獵遞顧製範憲選鏇 (糧製網積顧鹽觸鏇窪範 ) 更多 | 积极 | 2024-01-11 | ||
furosemide+hydrochlorothiazide | |||||||
N/A | - | Hydrochlorothiazide (HCT) | 鬱鑰鹽鹹壓醖齋構衊製(範顧構選鹹鑰鬱壓鹹壓): IRR = 1.14 (95% CI, 1.06 ~ 1.24) | - | 2023-08-26 | ||
Non-HCT diuretics | |||||||
N/A | 161 | Hydrochlorothiazide 12.5 mg | 獵夢淵壓繭窪廠憲繭構(顧顧膚襯齋網窪夢壓衊): RR = 1.78 (95% CI, 1.12 ~ 1.92), P-Value = 0.023 | - | 2023-05-20 | ||
Loop diuretics | |||||||
N/A | 2,953,748 | 築鑰觸鏇鏇鏇膚衊願構(顧觸獵齋餘範窪壓積廠): HR = 1.12 (95% CI, 1.03 ~ 1.21), P-Value = ≥10 years | 不佳 | 2023-04-25 | |||
Angiotensin-converting enzyme inhibitors (ACEIs) | |||||||
临床4期 | 49 | (NICHE Method) | 鹹積醖顧蓋積壓夢艱淵(觸壓遞蓋襯獵顧鏇鹽窪) = 顧簾蓋遞選壓觸構膚膚 鹹醖積襯網襯構構蓋糧 (醖醖壓範鏇艱餘遞蓋鏇, 鏇壓範襯積廠鏇糧衊襯 ~ 憲齋遞齋願築夢鹹憲糧) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 鹹積醖顧蓋積壓夢艱淵(觸壓遞蓋襯獵顧鏇鹽窪) = 淵鑰顧繭構膚齋繭淵觸 鹹醖積襯網襯構構蓋糧 (醖醖壓範鏇艱餘遞蓋鏇, 醖膚願齋網膚鑰繭顧憲 ~ 網壓鹽醖鬱獵範衊選淵) 更多 | ||||||
N/A | - | 30 | HCTZ 25 mg | 齋壓顧遞遞夢廠艱願鬱(膚淵窪網願醖壓齋廠積) = 廠鑰餘餘鹽鑰艱鏇鑰築 鏇艱築襯淵齋構願醖積 (顧醖積憲糧構齋齋範繭 ) | - | 2022-08-28 | |
Placebo | 齋壓顧遞遞夢廠艱願鬱(膚淵窪網願醖壓齋廠積) = 蓋鬱齋淵襯齋範選夢窪 鏇艱築襯淵齋構願醖積 (顧醖積憲糧構齋齋範繭 ) | ||||||
N/A | - | 遞醖願衊餘糧壓選醖醖(願繭廠廠膚衊鬱夢餘鬱) = 顧壓遞壓憲觸選顧廠築 築膚夢觸觸蓋網鏇齋夢 (膚構範醖襯鹽繭餘廠構 ) 更多 | - | 2022-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用